Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification

被引:0
|
作者
P. Font
J. Loscertales
C. Benavente
A. Bermejo
M. Callejas
L. Garcia-Alonso
A. Garcia-Marcilla
S. Gil
M. Lopez-Rubio
E. Martin
C. Muñoz
P. Ricard
C. Soto
P. Balsalobre
A. Villegas
机构
[1] Hospital General Universitario Gregorio Marañon,Department of Hematology
[2] Hospital Universitario de La Princesa,Department of Hematology
[3] Hospital Clinico San Carlos,Department of Hematology
[4] Hospital Universitario de Fuenlabrada,Department of Hematology
[5] Hospital Universitario Principe de Asturias,Department of Hematology
[6] Hospital Universitario de Getafe,Department of Hematology
[7] Hospital Universitario 12 de Octubre,Department of Hematology
[8] Hospital Universitario Puerta de Hierro,Department of Hematology
[9] Hospital Universitario Infanta Leonor,Department of Hematology
[10] Hospital Universitario Fundacion Alcorcon,Department of Hematology
[11] Fundación Jiménez Díaz,Department of Hematology
来源
Annals of Hematology | 2013年 / 92卷
关键词
Myelodysplastic syndromes (MDS); Morphology; WHO classification;
D O I
暂无
中图分类号
学科分类号
摘要
Morphology is the basis of the diagnosis of myelodysplastic syndromes (MDS). The WHO classification offers prognostic information and helps with the treatment decisions. However, morphological changes are subject to potential inter-observer variance. The aim of our study was to explore the reliability of the 2008 WHO classification of MDS, reviewing 100 samples previously diagnosed with MDS using the 2001 WHO criteria. Specimens were collected from 10 hospitals and were evaluated by 10 morphologists, working in five pairs. Each observer evaluated 20 samples, and each sample was analyzed independently by two morphologists. The second observer was blinded to the clinical and laboratory data, except for the peripheral blood (PB) counts. Nineteen cases were considered as unclassified MDS (MDS-U) by the 2001 WHO classification, but only three remained as MDS-U by the 2008 WHO proposal. Discordance was observed in 26 of the 95 samples considered suitable (27 %). Although there were a high number of observers taking part, the rate of discordance was quite similar among the five pairs. The inter-observer concordance was very good regarding refractory anemia with excess blasts type 1 (RAEB-1) (10 of 12 cases, 84 %), RAEB-2 (nine of 10 cases, 90 %), and also good regarding refractory cytopenia with multilineage dysplasia (37 of 50 cases, 74 %). However, the categories with unilineage dysplasia were not reproducible in most of the cases. The rate of concordance with refractory cytopenia with unilineage dysplasia was 40 % (two of five cases) and 25 % with RA with ring sideroblasts (two of eight). Our results show that the 2008 WHO classification gives a more accurate stratification of MDS but also illustrates the difficulty in diagnosing MDS with unilineage dysplasia.
引用
收藏
页码:19 / 24
页数:5
相关论文
共 50 条
  • [1] Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification
    Font, P.
    Loscertales, J.
    Benavente, C.
    Bermejo, A.
    Callejas, M.
    Garcia-Alonso, L.
    Garcia-Marcilla, A.
    Gil, S.
    Lopez-Rubio, M.
    Martin, E.
    Munoz, C.
    Ricard, P.
    Soto, C.
    Balsalobre, P.
    Villegas, A.
    ANNALS OF HEMATOLOGY, 2013, 92 (01) : 19 - 24
  • [2] Inter-observer agreement in myelodysplastic syndromes
    Ramos, Fernando
    Fernandez-Ferrero, Silvia
    HAEMATOLOGICA, 2013, 98 (07) : E77 - E77
  • [3] Inter-observer variance and the need for standardization in the morphological classification of myelodysplastic syndrome
    Sasada, Keiko
    Yamamoto, Noriko
    Masuda, Hiroki
    Tanaka, Yoko
    Ishihara, Ayako
    Takamatsu, Yasushi
    Yatomi, Yutaka
    Katsuda, Waichiro
    Sato, Issei
    Matsui, Hirotaka
    LEUKEMIA RESEARCH, 2018, 69 : 54 - 59
  • [4] WHO CLASSIFICATION 2016 FOR THE MYELODYSPLASTIC SYNDROMES (MDS): MAIN CHANGES
    Strupp, C.
    Aul, C.
    Germing, U.
    LEUKEMIA RESEARCH, 2017, 55 : S77 - S77
  • [5] WHO classification 2016 for the myelodysplastic syndromes (MDS): how to proceed
    Germing, U.
    Strupp, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 215 - 215
  • [6] Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
    Hebeda K.M.
    Fend F.
    Journal of Hematopathology, 2009, 2 (4) : 205 - 210
  • [7] The WHO classification of myelodysplastic syndromes (MDS) does make a difference.
    Howe, RB
    Porwit, A
    Wanat, R
    Tehranchi, R
    Hellstrom-Lindberg, E
    BLOOD, 2002, 100 (11) : 790A - 791A
  • [8] CLASSIFICATION AND TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS)
    CATOVSKY, D
    MYELODYSPLASTIC SYNDROMES : PATHOPHYSIOLOGY AND TREATMENT, 1988, 783 : 3 - 3
  • [9] Inter-observer reliability for the diagnosis of lung cancer in a clinical cohort using the WHO classification system, version
    Grilley-Olson, J. E.
    Hayes, D. N.
    Miller, R. D.
    Socinski, M. A.
    Stinchcombe, T. E.
    Hayward, M.
    Qaqish, B. F.
    Moore, D. T.
    Funkhouser, W. K., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] The WHO classification of the myelodysplastic syndromes
    Bain, B
    EXPERIMENTAL ONCOLOGY, 2004, 26 (03) : 166 - 169